Chaired by Marisol Touraine, former French Minister of Social Affairs, Health and Women’s Rights, 2012-2017, the Executive Board consists of 13 members who make decisions by consensus.
Chaired by Marisol Touraine, former French Minister of Social Affairs, Health and Women’s Rights, 2012-2017, the Executive Board consists of 13 members who make decisions by consensus.
Chair of the Executive Board
After studying at the Ecole normale supérieure for a degree in economics and social sciences, Marisol Touraine studied at the Institut d'études politiques of Paris and at the prestigious Harvard University in the United States. Advisor to the Prime Minister from 1988 to 1991 on geostrategic issues, she became a member of the Conseil d'Etat in 1991. She then served at political positions at local level and within the French Parliament for several years before being appointed Minister of Social Affairs, Health and Women's Rights (2012-2017). Of particular note in this role was her support to authorize and to assure financial coverage for innovative preventive HIV treatments, as well as her fight for the neutral cigarette pack, acknowledged by the WHO prize in 2016. She is Chair of the Unitaid Executive Board since June 2019.
Representing Brazil / Vice-chair of the Executive Board
Born in Curitiba, Paraná, on 12 April 1971. She holds a degree in Law and has been a career diplomat since 1996, after concluding her studies at the Brazilian Diplomatic Academy. She also holds a post-graduate degree in Foreign Trade from Fundação Getúlio Vargas, Brasília-DF, and a Masters degree in Public Administration (MPA) from Columbia University, NY. She served at the Brazilian Consulate General in New York, at the Brazilian Embassy to Colombia and at the Brazilian Embassy to the United Kingdom. In the Foreign Ministry headquarters in Brasilia, she has worked as an Assistant to the Director General of the Trade Promotion Department and to the Undersecretary General for Africa, Asia, the Middle East and the Pacific. In the seven years prior to her present appointment, she was the Head of Japan and Korean Peninsula Division, acting Director of East Asia Department, Assistant and Deputy-Chief of Staff to the Secretary-General and subsequentially Director General of the Department of Japan, Korean Peninsula and the Pacific.
African countries / Board member
African countries / Alternate
Brazil / Alternate
Chile / Board member
Chile / Alternate
Communities living with the diseases / Board member
Communities living with the diseases / Acting Alternate
Foundations / Board member
Foundations / Alternate
France / Board member
France / Alternate
Japan / Board member
Japan / Alternate
NGOs / Board member
NGOS / Alternate
Norway / Board member
Norway / Alternate
Republic of Korea / Board member
Republic of Korea / Alternate
Spain / Board member
Spain / Alternate
United Kingdom / Board member
United Kingdom / Alternate
World Health Organization / Board member
World Health Organization / Alternate
Supports Unitaid’s financial planning and management
Terms of reference [PDF]
Advises the Board on strategic planning and core policies, reviews the performance of Unitaid’s portfolio and responds to policy recommendations from expert advisory groups.
Terms of reference [PDF]
An independent, impartial team of experts who provide guidance to Unitaid on proposals submitted for funding and in grant development. Their expertise covers science, public health, health systems, programming, country implementation, market dynamics and health economics
Terms of reference [PDF]
PRC Chair
Andy Gray B Pharm, MSc (Pharm), FPS, FFIP is a pharmacist whose research interests include policy analysis (in particular, the development and implementation of National Medicines Policies), rational medicines use and the application of antiretroviral therapy in resource-constrained settings. He is a Senior Lecturer in the Division of Pharmacology, Discipline of Pharmaceutical Sciences, School of Health Sciences, University of KwaZulu-Natal, Durban, South Africa. He is also consultant pharmacist (research associate) for the Centre for the AIDS Programme of Research in South Africa (CAPRISA).
PRC Core Members
Enrica Alteri MD, DiplPharmMed
After completing her medical studies in Rome and a postdoctoral fellowship at the National Cancer Institute in Bethesda (USA), Dr Alteri spent 25 years in the pharmaceutical industry, where she was involved in major projects that yielded important drugs such as Gleevec for myeloid leukaemia, Coartem for malaria and Reyataz for HIV-AIDS.
In 2012 she joined the European Medicines Agency, where she was Head of Human Medicines R&D support Division, and member of the Executive Board.
In these roles, Dr Alteri was part of many high impact EMA’s initiatives, from the transparency of clinical trial data to the development of regulatory science strategy to 2025.
Dr Alteri is currently a member of the Scientific Committee and faculty of the master course in Drug R&D of the University of Geneva, and master courses in R&D at the Luiss University and Universita’ Cattolica in Rome.
Dr Blaise Bikandou MD, PhD, MBA is a Public Health Doctor and Senior Expert in International Health with a strong orientation towards health systems. He is currently member of the PRC for Unitaid and TRP for Global Fund. Previously, he has led AMP Office in Guinea, worked at the Paris Hospitals, headed the department of preventive medicine, epidemiology, and clinical trials at the National Institute of Public Health of Congo-Brazzaville. He has a MD supplemented by a medical specialty diploma (René Descartes-Paris), a master in communicable diseases (Massachusetts Medical School, US), a PhD in molecular biology, immunology and virology (René Descartes-Paris/Kyoto University-Japan), Diplomas in Immunology & Vaccination – Clinical Trials (Institute Pasteur, Paris) and Health MBA (ESCP-EHSP/Europe, Columbia University, NY).
Miranda Brouwer is a Public Health physician with over 15 years’ experience in global health supporting countries and programmes with TB and TB/HIV. She works as an independent consultant conducting evaluations and providing technical assistance and capacity building, amongst other support. She has a PhD on implementation of guidelines and has published widely on tuberculosis control and on monitoring and evaluation.
A public health professional with pharmacist background, Kashi has over 15 years of experience working in developing countries on policy, strategy, design and implementation of access to medicine programs. Her key skills include procurement & supply chain management, system strengthening and training & capacity building. Kashi has experience working with a range of development partners, including national governments, WHO, DFID, the Global Fund, USAID, World Bank, Clinton Foundation, MSF and academia. She has served as a member of Unitaid’s PRC since 2014.
Bernard Fourie is a medical microbiologist with a career focus in tuberculosis, particularly translational research on rapid diagnostic methods, inhaled therapies and vaccination, and clinical trials of anti-TB medications and other interventions. He is currently attached to the Department of Medical Microbiology at the University of Pretoria and formerly served as the Director of the Tuberculosis Research Institute and of the MRC National TB Research Programme in South Africa. Apart from Unitaid, he has provided expert technical support in the field of tuberculosis over many years to international organizations such as WHO, UNIDO, EDCTP, GIZ, and locally to the South African Medicines Control Council.
A PRC Member since 2010, Cheri Grace has 30 years of work experience in a variety of work sectors and organisation types – pharmaceutical industry; corporate finance; grassroots development; academic research, global health consulting. For 15+ years, Cheri has worked as a strategy advisor to aid finance organisations/donors, bringing commercial business knowledge as well as understanding of the strategic direction of various funders, progress and challenges in global health and the wider development aid environment, and experience working in more than 20 aid recipient countries. Previously a Senior Health Advisor in DFID, Cheri led DFID’s work through Product Development Public-Private Partnerships, and supported work in Advance Market Commitments and the broader Access to Medicines agenda. Cheri is also a focal point for the Global Fund Technical Review Panel.
Lulu Muhe is an adjunct professor of pediatrics and Child Health in Addis Ababa University, Ethiopia since 2015. Before that he worked with the World Health Organization in Geneva and in AFRO in the areas of pediatric infectious diseases such as HIV, malaria, tuberculosis, diarrhea and pneumonia mainly supporting research, policy development and capacity building, monitoring and evaluation in many developing countries.
Dr. Giorgio Roscigno is a senior and passionate public health specialist with a very long experience in the private and public sectors. He has been working as medical doctor from 1972 to 1982 in Ethiopia Sudan DRC Algeria and Italy. In 1982 he joined the pharmaceutical Industry and worked in Switzerland France the UK and Italy. He left the Industry in 2000: during this period he developed up to FDA approval all the fixed dose combinations for TB, the first nontoxic drug for Sleeping Sickness and Rifapentine. From 2000 to 2014 he has been involved as Founder and CEO of the Global Alliance for TB (2000/2003); FIND (2003/2013) , The African Society for Laboratory Medicine( COO 2013/2014) and NEXT2PEOPLE ( Executive Chair 2015 -now). Dr. Roscigno has been actively involved in the creation of the Stop TB Partnership and covered overtime positions in the Board and chaired Working Groups in Drugs and Diagnostics.
Anne-Marie Taburet, PharmD, PhD, is a consultant in clinical pharmacokinetics and coinvestigator of ANRS sponsored clinical trials including some conducted in resource limited countries. She was the head of the clinical pharmacy department of a Paris University hospital. She has expertise in drug supply and care of patients with HIV, tuberculosis, HIV coinfections including some resource limited countries and participated to training of health care providers. She was first appointed to Unitaid PRC in 2013.
PRC Disease/Issue-Specific Members
E. Jane Carter, MD, is Associate Professor of Medicine (Pulmonary and Critical Care Division) at Warren Alpert School of Medicine at Brown University in Providence, RI, USA. She is the immediate past president of The International Union Against TB and Lung Disease (The Union). Her work in international tuberculosis has focused on implementation science in intensified case finding, program development and removal of access barriers, and addressing the pediatric care cascade in resource constrained areas, focused primarily in East Africa.
Betina Durovni is a medical doctor specialized in infectious diseases whose career started in the centre of the AIDS epidemic in 1986. After many years as a clinician, Dr Durovni became interested in Public Health and Health administration. She holds a MBA in health administration and a PhD in medicine from the Rio de Janeiro Federal University and a MPH from the Johns Hopkins University. Dr Durovni has served as a consultant for Brazilian MoH and UNAIDS with experience in several countries. Dr Durovni also has experience in operational research and team leadership in international collaborations in projects in tuberculosis, HIV and primary care. Dr Durovni has also interest in the primary care and helped to implement the health care reform in Rio de Janeiro as undersecretary for surveillance, promotion and primary care.
Gilles Raguin is a medical doctor, trained in internal medicine and infectious diseases, and a global health specialist with more than 20 years of experience with hospital work, governmental and non-governmental organizations.Combining a very good knowledge of global health actors and funders with a strong experience in clinical practice, humanitarian aid and technical expertise, Dr Raguin is particularly experienced in the fields of infectious diseases, global health security and humanitarian health in resource limited countries.
Ross McLeod, an economist with 20+ years’ experience in market access, health outcomes and economic modelling who currently works as an economics advisor to the Royal Australasian College of Surgeons. He has served as a member of the Global Fund to Fights AIDS, TB and Malaria and GAVI proposal review panels, along with advising the Commission for AIDS in Asia and Asian Development Bank. He has a PhD in economic evaluation and holds postgraduate degrees in public health from the University of Oxford and London School of Hygiene and Tropical Medicine.